...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009-2010 season
【24h】

A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009-2010 season

机译：美国上市后评估，对不推荐5岁以下儿童使用减毒活疫苗的频率和安全性：2009-2010赛季

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The 2007 US approval for use of Ann Arbor strain live attenuated influenza vaccine (LAIV) in children aged 24 through 59 months included precautions against use in (1) children <24 months and children aged 24 through 59 months with (2) asthma, (3) recurrent wheezing, and (4) altered immunocompetence. Results from the third season (2009–2010) of a 3-year study postmarketing commitment to monitor LAIV vaccination rates and frequency of hospitalizations or emergency department visits within 42 days after LAIV are reported here. As in the first 2 seasons, LAIV usage in cohorts 1, 2, and 4 were low relative to those in LAIV-recommended populations. The only numerically increased risk observed was for respiratory events in children aged <24 months administered LAIV, compared to those administered trivalent inactivated influenza vaccine (TIV). The number of children vaccinated with LAIV was small and precluded precise quantification of rare event.
机译：2007年美国批准在24至59个月大的儿童中使用Ann Arbor毒株减毒活疫苗（LAIV），其中包括预防（1）年龄＜24个月的儿童和24至59个月大的儿童（2）哮喘的预防措施， 3）反复喘息，以及（4）免疫能力改变。此处报告了一项为期3年的上市后承诺研究的第三季（2009-2010年）的结果，该承诺旨在监测LAIV接种率以及LAIV后42天内住院或急诊就诊的频率。与前两个季节一样，队列1、2和4中的LAIV使用率相对于LAIV推荐人群中的较低。与使用三价灭活流感疫苗（TIV）的儿童相比，观察到的唯一数字上增加的风险是接受LAIV的24岁以下儿童的呼吸系统事件。接受LAIV疫苗接种的儿童人数很少，因此无法精确量化罕见事件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号